Types of drug therapies
There are two main types of drugs available for the treatment of schizophrenia: oral drugs and injections.
What are the advantages of these two types of therapies?
|Oral drugs||Long-acting injections|
|Easy to use||Can reduce the risk of relapse16|
|Conventional||Long lasting effect|
|Seems familiar||It allows thinking about the disease and the therapy only four times a year, monthly or every two weeks|
|It creates the feeling of independence and control||Less conflicts with relatives related to verifying whether the patient took the drugs or not|
|Regular contacts with the doctor|
What are the disadvantages of these two types of therapies?
|The patient has to think of taking the drug every day||Possible pain and swelling at the injection site|
|The patient may forget to take the drug||If there is any side effect, which require switching therapies, this could take longer|
|The patient is at higher risk of deterioration and hospitalization compared to long-action injections26|
1. APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004
2. Falkai P et al. World J Biol Psychiatry 2005; 6: 132-191.
3. Kendler KS et al. Arch Gen Psychiatry 1996; 53: 1022-1031.
4. World Health Organization. The World Health Report: 2001: Mental health: new understanding, new hope.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR). Arlington: American Psychiatric Publishing Inc. 2000.
6. Lieberman JA et al. J Clin Psychiatry 1996; 57(suppl 9): 5-9.
7. Breier A et al. Am J Psychiatry 1994; 151: 20-26.
8. Robinson DG et al. Am J Psychiatry 1999; 156: 544-549.
9. National Institute for Clinical Excellence. National Clinical Practice Guidelines Number 82.
10. Howard R et al. Am J Psychiatry 2000; 157: 172-178.
11. Angermeyer MC et al. Schizophr Bull 1990; 16: 293-307.
12. Murray RM and Fearon P. J Psychiatr Res 1999; 33: 497-499.
13. Lang UE et al. Cell Physiol Biochem 2007; 20: 687-702.
14. Harrigan SM et al. Psychol Med 2003; 33: 97-110.
15. Bottlender R et al. Schizophr Res 2003; 62: 37-44.
16. Lynn Starr h. et al: Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study; Schizophr Res. 2018 Apr;194:39-46. doi: 10.1016/j.schres.2017.05.005. Epub 2017 Jun 7
17. Awad AG et al. Pharmacoeconomics 2008; 26: 149-162.
18. Keith SJ et al. Psychiatr Serv 2004; 55: 997-1005.
19. Lieberman JA et al. Pharmacol Rev 2008; 60: 358-403.
20. Tandon R et al. Psychoneuroendocrinology 2003; 28(suppl 1): 9-26.
21. Wyatt RJ. Schizophr Bull 1991; 17: 325–351
22. Robinson DG et al. Arch Gen Psychiatry 1999; 56: 241-247.
23. Weiden PJ et al. Psychiatr Serv 2004; 55: 886-891.
24. Koen L et al. Psychosomatics 2007; 48: 128-134.
25. Novick D et al. Psychiatry Res 2010; 176: 109-113.
26. Kozma CM et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Research and Opinion. 2011.27;1603-1611